[CAS NO. 112228-65-6] B220
PRODUCTS SPECIFICATIONS [112228-65-6]
DESCRIPTION [112228-65-6]
Overview
| MDL | MFCD00835300 |
|---|---|
| Molecular Weight | 318.42 |
| Molecular Formula | C20H22N4 |
| SMILES | CC1=C(C)C=C2N=C3C(N(CCN(C)C)C4=C3C=CC=C4)=NC2=C1 |
Summary
IC50 & Target
|
HSV-1 |
HSV-2 |
In Vitro
B220 is an antiviral agent which can inhibit the growth of HSV-1, HSV-2 and human cytomegalovirus (CMV) [1] . B220 inhibits neutrophil release of reactive oxygen species, as well as intracellular generation of reactive oxygen species. The inhibition is not achieved through direct oxygen radical scavenger activity of B220, and B220 has no immediate effects on the activity of the assembled oxidase. The neutrophil capability to phagocytose fluorescein-labeled opsonized yeast cells is reduced by B220. Cells preincubated with B220 (10 µg/mL) and then stimulated with the formylated peptide fMLP mobilize fewer C3 receptors on their surface than the control cells [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
References
- [1] Mohammed Homman, et al. Pharmaceutical formulation of B220 for topical treatment of herpes. EP 2489354 A1.
- [2] Harbecke O, et al. The synthetic non-toxic drug 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline inhibits neutrophil production of reactive oxygen species. J Leukoc Biol. 1999 Jun;65(6):771-7.